A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn’t live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe